Our passion is to find and unleash the best innovations that could transform health outcomes for patients, wherever they originate.  Located in innovation hubs around the world, we work hand-in-hand with innovators, helping accelerate their ideas with industry-leading incubation and investment support, and deep scientific and commercial expertise from the Johnson & Johnson family of companies. 

Our portfolio is a result of our innovation-based strategy and deep scientific expertise, world-class capabilities and a source-agnostic, win-win approach to external innovation, which includes a significant investment in both Business Development and Research & Development. We remain highly active in sourcing external innovation, seeking opportunities that will best complement our existing in-market portfolio and pipeline to enable us to help elevate the standard of care for patients. 

Our goal is to identify collaborative opportunities and form active partnerships where we can bring the full strength of Johnson & Johnson to bear to create transformative value for our partners and the world. Our areas of interest include:  

• Oncology – Including Myeloid Leukemia, B-cell Lymphoma, Multiple Myeloma, Bladder Cancer, Lung Cancer, Prostate Cancer and Immuno-Oncology.
   
• Immunology – Including Crohn’s Disease, Ulcerative Colitis, Celiac, Inflammatory Bowel Disease, Maternal Fetal Disease, Autoantibody driven Diseases, Psoriasis, Psoriatic Arthritis, Atopic Dermatitis, Rheumatoid Arthritis, Sjogren’s, and Systemic Lupus Erythematosus.
   
• Neuroscience – Including Alzheimer’s, Parkinson’s, Depression, Bipolar Disorder, Schizophrenia, and Neurological autoantibody driven diseases.
   
• Cardiopulmonary – Including Atrial Fibrillation, Stroke, Cardiomyopathy, Thrombosis, Heart Failure, Pulmonary Hypertension, and Pulmonary Fibrosis.
   
• Specialty Ophthalmology – Including Geographic Atrophy, Inherited Retinal Disorders, Retinal Vascular Diseases, and Thyroid Eye Disease.
   
• Discovery, Product Development, and Supply – Including small molecules, Protein Therapeutics, mRNA and SiRNA Therapeutics, Drug delivery solutions, and Supply chain technologies.
   
• Data Sciences and Digital Health – AI and ML approaches for target and biomarker identification, molecular invention, CMC, clinical trial design and process enhancement; novel digital endpoints and diagnostics.
   
• Interventional Oncology – Including Intratumoral delivery, Radiation/Drug combinations, and Therapeutic Energy.